Wockhardt Limited
WOCKPHARMA
Hisse Senetlerindeki Sıralama
#4519
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Hisse Fiyatı
$21.04
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$3.42B
Değişim (1 gün)
-2.39%
Değişim (1 yıl)
34.90%
Ülke
IN
Ticaret Wockhardt Limited (WOCKPHARMA)
Kategori
Healthcare
Wockhardt Limited (WOCKPHARMA) için kazanç
Jun 2026 itibarıyla kazanç TTM: $51.10M
Wockhardt Limited şirketinin en son finansal raporlarına göre, mevcut kazancı $51.10M'dir. 2024 yılında şirket $-50.37M kazanç elde etti, bu 2023 yılındaki $-75.93M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Wockhardt Limited için kazanç geçmişi 2004 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $51.10M | -2,831.29% |
| 2025 | $-1.87M | -96.29% |
| 2024 | $-50.37M | -33.66% |
| 2023 | $-75.93M | 40.24% |
| 2022 | $-54.14M | -30.22% |
| 2021 | $-77.59M | 70.90% |
| 2020 | $-45.40M | -29.40% |
| 2019 | $-64.31M | -34.69% |
| 2018 | $-98.47M | 158.38% |
| 2017 | $-38.11M | -187.03% |
| 2016 | $43.79M | -52.51% |
| 2015 | $92.20M | -37.95% |
| 2014 | $148.59M | -56.05% |
| 2013 | $338.11M | 197.28% |
| 2012 | $113.73M | 385.74% |
| 2011 | $23.41M | -110.67% |
| 2010 | $-219.46M | 324.20% |
| 2008 | $-51.73M | -142.94% |
| 2007 | $120.48M | 81.57% |
| 2006 | $66.36M | 1.54% |
| 2005 | $65.35M | 13.32% |
| 2004 | $57.67M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $1.35B | 2,541.82% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -48.39% |
US
|
